The department of Proteomics and Signal Transduction is headed by Prof. Matthias Mann and was established in 2005. Matthias Mann is the highest cited German researcher by his h-index of more than 240 and over 270,000 citations ( google scholar). In addition to his group at the Max Planck Institute of Biochemistry, Matthias Mann is the director of the proteomics program at the Novo Nordisk Foundation Center for Protein Research (NNF-CPR) in Copenhagen where he also leads the Clinical Proteomics group ( clinical proteomics group). The Mann lab is a leader in the technology and application of mass spectrometry-based proteomics and has been at the forefront of the field for over two decades. The core research interests of the group are signal transduction, biomarker discovery and metabolic diseases. Another focus is the development of mass spectrometric and proteomic methods for application in biological and clinical contexts. The group is also developing computer algorithms for automated identification and quantification of peptides as well as systems biological and clinical knowledge mining. Ultimately, our vision is to transfer proteomics knowledge into clinics for predictive, diagnostic and preventive purposes. We are a highly collaborative team and involved in several networks including MICROB-PREDICT, Michael J. Fox Foundation for Parkinson’s Research projects, German-Israeli project (DIP), CLINSPECT-M, Munich Heart Alliance, and Digimed Bayern.
Matthias Mann gives a research lecture at the Nobel Forum at the Karolinska Institute
Matthias Mann talks about clinical proteomics in interview with Evosep Biosystems
S. Babak Azimifar, Nagarjuna Nagaraj, Juergen Cox, Matthias Mann
Image: Max Iglesias